Intro
Golomb Research Group
"The UC San Diego Golomb Research Group, headed by Dr. Beatrice Golomb, studies many different conditions related to oxidative stress and cell energy impairments. We are currently working with Gulf War Veterans, as well as with people experiencing side effects from fluoroquinolone antibiotics, statin cholesterol lowering medications, radiofrequency radiation (and other non-ionizing radiation) – e.g., from cell towers or smart meters, and persons affected by the toxin release following the 2023 train derailment in East Palestine, Ohio.”
Intro
Golomb Research Group
"The UC San Diego Golomb Research Group, headed by Dr. Beatrice Golomb, studies many different conditions related to oxidative stress and cell energy impairments. We are currently working with Gulf War Veterans, as well as with people experiencing side effects from fluoroquinolone antibiotics, statin cholesterol lowering medications, radiofrequency radiation (and other non-ionizing radiation) – e.g., from cell towers or smart meters, and persons affected by the toxin release following the 2023 train derailment in East Palestine, Ohio.”
NEW: East Palestine (Ohio) Toxin Health Effects Study
To donate, click HERE.
About our Research
We are currently recruiting Gulf War Veteran participants. We are also interested in hearing from you if you have had an adverse reaction to a statin drug, fluoroquinolone, pesticide, vaccine or electromagnetics. To learn more about our research and how to get involved, click HERE.
About our Staff
The Golomb Research Group is headed by Dr. Beatrice Golomb, professor of medicine at the University of California, San Diego. Her research support staff is one of a kind. Get to know Dr. Golomb and the staff by clicking HERE.
In the News
The research from the Golomb Research Group is often featured in the media. Recently, Dr. Golomb's research has been featured many times in the New York Times, the Wall Street Journal, the Washington Post, and the San Diego Union Tribune. Some of these articles are listed on our press page.